[Clinical use of ceftazidime in the field of obstetrics and gynaecology].
Clinical effect and safety of ceftazidime (CAZ) in the obstetrics and gynaecology were studied in 7 cases of intrauterine infections, 8 cases of parametritis, 1 case of Bartholin's abscess, and 4 cases of intrapelvic infections totalling 20 cases. CAZ was administered at a dose of 2 g per day by intravenous drip infusion, for 4--9 days depending on severity of the disease. The results showed that CAZ was effective in 13 out of 20 cases (overall efficacy rate 65%), and especially in intrauterine infections, it was effective in all the cases. However, effects were not satisfactory in 8 cases of parametritis and 4 cases of intrapelvic infections for various reasons such as influences of underlying diseases including cancer. Neither adverse reactions nor abnormal laboratory findings attributable to CAZ were observed during the treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D010249:Parametritis / Q000188:drug therapy; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy; D011247:Pregnancy; D014591:Uterine Diseases / Q000188:drug therapy
D002511:Cephalosporins; D002442:Ceftazidime